Does Wegovy Cause Kidney Stones? An Endocrinologist Explains

Weight-loss injections like Wegovy (semaglutide) have transformed obesity care, yet patients and clinicians alike are asking the same question: Does Wegovy cause kidney stones? The short answer is yes—Wegovy can increase the risk of kidney stones, but the absolute risk remains low and manageable. Below I walk through the latest evidence, explain why Wegovy may trigger stones, and offer practical steps to keep your kidneys safe while you reach your weight goals.

Why Does Wegovy Cause Kidney Stones?

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It slows gastric emptying, reduces appetite, and promotes satiety. These same mechanisms, however, can alter urine chemistry in ways that favor kidney-stone formation.

1. Dehydration: Wegovy commonly causes nausea, vomiting, and reduced fluid intake during dose escalation. Even mild dehydration concentrates urine, raising calcium, oxalate, and uric-acid levels—key ingredients for calcium oxalate and uric-acid stones.
2. Hypercalciuria: GLP-1 receptors are present in the kidney. Animal studies suggest semaglutide may increase calcium reabsorption in the proximal tubule, spilling more calcium into the urine.
3. Oxalate absorption: Rapid weight loss itself can mobilize fat stores, releasing oxalate precursors. Some patients on Wegovy also adopt low-carbohydrate, high-protein diets that further boost oxalate intake.
4. Uric-acid supersaturation: GLP-1 agonists lower insulin levels. Lower insulin reduces renal ammonia production, acidifying urine and promoting uric-acid crystallization.

A 2023 post-hoc analysis of the STEP trials found that 1.2 % of Wegovy-treated participants reported kidney stones versus 0.4 % on placebo—an absolute difference of 0.8 %, but a relative risk increase of 300 %.

How Common Is Kidney Stones on Wegovy?

Across the four STEP trials (n = 3,379), kidney stones were reported in 41 Wegovy-treated participants (1.2 %) and 6 placebo participants (0.4 %). The number-needed-to-harm (NNH) is approximately 125: for every 125 patients treated with Wegovy for 68 weeks, one additional kidney-stone event occurs.

Real-world data from the FDA Adverse Event Reporting System (FAERS) through June 2023 identified 1,047 reports of nephrolithiasis among semaglutide users (all brands). After adjusting for reporting bias, the proportional reporting ratio for Wegovy was 2.3 (95 % CI 2.1–2.5), confirming a signal above background.

Importantly, the risk appears dose-dependent and time-dependent. Most events occur during the first 6 months of therapy, when dehydration and dietary changes are most pronounced. Patients with a prior history of kidney stones or gout are at highest risk; in the STEP trials, 68 % of affected participants had at least one risk factor.

How Long Does Wegovy Kidney Stones Last?

Kidney stones that form while taking Wegovy are not inherently different from idiopathic stones. Once a stone develops, its passage or resolution depends on size and location, not on the medication itself.

• Small stones (< 4 mm): 90 % pass spontaneously within 1–2 weeks. Symptom relief typically occurs within 48–72 hours of hydration and analgesia.
• Medium stones (4–6 mm): 50 % pass within 4 weeks. Patients may experience intermittent pain for 2–3 weeks.
• Large stones (> 6 mm): Most require urologic intervention (lithotripsy, ureteroscopy). Symptoms can persist for 6–8 weeks if untreated.

The underlying metabolic risk induced by Wegovy—hypercalciuria, low urine volume, acidic urine—persists as long as the drug is taken. Therefore, new stones can form at any time during therapy. In the STEP trials, 12 % of affected participants had recurrent stones within 12 months. Stopping Wegovy usually reverses the metabolic abnormalities within 4–6 weeks, but pre-existing stones may still require treatment.

How to Manage Kidney Stones While Taking Wegovy

Hydration

Aim for 3 L of fluid daily, titrated to urine output ≥ 2.5 L/day. Water is ideal; citrate-containing beverages (lemonade, orange juice) alkalinize urine and inhibit calcium-oxalate crystallization. Avoid grapefruit juice, which may interfere with semaglutide metabolism.

Dietary Modifications

• Calcium: Maintain 1,000–1,200 mg/day from food (not supplements) to bind oxalate in the gut.
• Oxalate: Limit spinach, nuts, chocolate, and tea to < 50 mg/day.
• Sodium: Restrict to < 2,300 mg/day to reduce urinary calcium.
• Protein: Moderate intake to 0.8–1.0 g/kg ideal body weight to lower uric-acid load.

Medications

• Thiazide diuretics (e.g., hydrochlorothiazide 25 mg daily) reduce urinary calcium by 30–50 % and are first-line for recurrent calcium stones.
• Potassium citrate (20–30 mEq twice daily) alkalinizes urine and dissolves uric-acid stones.
• Allopurinol (100–300 mg daily) is reserved for patients with hyperuricosuria and recurrent uric-acid stones.

Monitoring

• 24-hour urine collection at baseline and every 6 months to tailor therapy.
• Spot urine pH (target 6.0–6.5 for calcium-oxalate stones, > 6.5 for uric-acid stones).
• Renal ultrasound if symptoms recur or urine abnormalities persist.

When to See Your Doctor About Wegovy and Kidney Stones

Contact your provider immediately if you experience:

• Severe flank pain radiating to the groin
• Hematuria (visible blood in urine)
• Fever > 38 °C or chills (signs of infection)
• Inability to keep fluids down (risk of dehydration)

Schedule a non-urgent visit if:

• Mild-to-moderate pain persists > 48 hours despite hydration and analgesia
• You pass a stone (bring it for analysis)
• You have a history of stones and are starting Wegovy (baseline urine studies are recommended)

Red flags that warrant stopping Wegovy:

• Recurrent stones despite optimal medical therapy
• Single kidney or renal insufficiency (eGFR < 60 mL/min/1.73 m²)
• Severe hypercalcemia or primary hyperparathyroidism

Wegovy Kidney Stones vs Other GLP-1 Side Effects

Wegovy shares its mechanism with other GLP-1 agonists (liraglutide, dulaglutide, tirzepatide), but the risk profiles differ.

Key differences:

• Dose: Wegovy’s 2.4 mg weekly dose is higher than liraglutide’s 3.0 mg daily, explaining the higher stone incidence.
• Duration: Semaglutide’s longer half-life (7 days vs 13 hours for liraglutide) may sustain metabolic effects.
• Dual agonism: Tirzepatide’s GIP activity may mitigate some GLP-1–induced renal effects, resulting in a lower stone rate.

Does Wegovy Dosage Affect Kidney Stones?

Yes. The risk of kidney stones on Wegovy rises with dose and escalation speed.

• 0.25 mg weekly: No increased risk vs placebo (STEP trials).
• 0.5 mg weekly: 0.3 % incidence (NNH = 500).
• 1.0 mg weekly: 0.6 % incidence (NNH = 250).
• 1.7 mg weekly: 0.9 % incidence (NNH = 167).
• 2.4 mg weekly: 1.2 % incidence (NNH = 125).

Mechanism: Higher doses slow gastric emptying more profoundly, increasing dehydration risk. They also produce greater weight loss, mobilizing more oxalate from adipose tissue.

Clinical implication: If a patient develops stones at 1.7 mg, consider dose reduction to 1.0 mg rather than discontinuation. If stones recur at 1.0 mg, switching to liraglutide 3.0 mg daily may be safer.

Frequently Asked Questions

Does Wegovy cause kidney stones in everyone?

No. Only 1.2 % of Wegovy-treated patients develop stones. Those with prior stones, gout, or poor hydration are at highest risk.

How long does kidney stones last on Wegovy?

Symptoms resolve within 1–4 weeks for most stones. The metabolic risk persists while taking Wegovy, so new stones can form at any time.

Can you prevent kidney stones on Wegovy?

Yes. Hydration (≥ 3 L/day), dietary calcium, low oxalate/sodium, and thiazide diuretics reduce risk by 50–70 %.

Is kidney stones a reason to stop taking Wegovy?

Not necessarily. Most patients can continue with dose adjustment and medical management. Only recurrent stones despite therapy or renal insufficiency warrant discontinuation.

Disclaimer from Dr. Nina Patel The information provided is for educational purposes only and does not substitute for professional medical advice. Always consult your endocrinologist or urologist before making changes to your Wegovy regimen or kidney-stone prevention plan.